Home | Welcome to Contract Pharma   
Last Updated Friday, November 28 2014
Print

Icon Bioscience Appoints CEO



Published April 7, 2014
David S. Tierney, MD has been appointed president and chief executive officer of Icon Bioscience, Inc. Dr. Tierney is an accomplished healthcare executive with significant experience in successfully developing and commercializing drug delivery platforms. He will apply his expertise to Icon’s Verisome technology platform to develop unique intraocular eye-care therapeutics.
 
Dr. Tierney previously served as president and chief operating officer of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in 2008, which was later acquired by Salix Pharmaceuticals in 2011. Dr. Tierney also served as president and chief executive officer of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS became Valera Pharmaceuticals, an integrated, commercial, specialty pharma company that successfully completed an IPO in 2005. Valera has since been merged into Endo Pharmaceuticals.
 
"We are delighted to have David join our team,” said Vernon G. Wong, MD, chairman and founder of Icon Bioscience and inventor of Verisome. “David possesses a wealth of expertise in medical science, clinical and regulatory affairs, and in overseeing the advancement of healthcare companies through the product development phase to commercial operations, key elements in support of Icon’s exciting growth outlook.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On